Compare Enovix Corporation (ENVX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Twist Bioscience Corp — how do they compare? Enovix Corporation trades at $4.59 (market cap $1.11B), while Twist Bioscience Corp trades at $90.24 (market cap $5.76B). The key difference: Twist Bioscience Corp is far larger — about 5.2× Enovix Corporation's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | TWST | |
|---|---|---|
Market Cap | $1.11B | $5.76B |
Sector | Technology | Health |
52-Week High | $15.93 | $102.88 |
52-Week Low | $4.84 | $24.16 |
Enterprise Value | $1.13B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX is trading at $4.59, down 9.29% in the last session, with a bearish technical signal. The company shows consistent quarterly earnings beats but remains deeply unprofitable with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in commercial battery production for smart eyewear and smartphone markets.
Despite analyst optimism (75% buy ratings, $12.75 consensus target), ENVX faces significant execution risks as it scales production. The stock offers speculative growth potential in advanced battery technology but requires substantial revenue acceleration to justify current valuations amid persistent cash burn and negative profitability.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
